The intracellular Janus kinase (JAK)-STAT cascade plays a role both in SLE and psoriasis, and several JAK inhibitors have been trialled in both diseases.46, 48 Recently, a phase II randomised controlled trial (RCT) reported data favouring the use of upadacitinib in SLE,49 a drug approved for treating PsA.50 Here, SOAT1 is linked to systemic lupus erythematosus.